Read Taconic's response to coronavirus (COVID-19), and visit our toolkit for researchers. Learn More
huPBMC-NOG

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • huPBMC-NOG-F
    sp/sp;ko/ko
    NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac
  • huPBMC-NOG-M
    sp/sp;ko/y
    NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac
  • huPBMC-NOG is a model for investigation of adult/mature cell populations.
  • This model permits the assessment of effector and memory T cells.
  • Human peripheral blood mononuclear cell (PBMC) engrafted mice are optimally suited for studies immediately following engraftment as Graft vs. Host Disease (GvHD) limiting survival time to 4-6 weeks. In addition, the GvHD response can be used as a screening system for T cell modulating drugs, with readouts including body weight and clinical condition, liver injury and immune cell infiltration into organs.
  • See Søndergaard et al. and Cox et al. for description of the GvHD model and its use in drug target validation.
  • Inquire about options such as irradiation, PBMCs of specific donor HLA types or patient-derived PBMCs.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Related Taconic InsightRead the Related Taconic Biosciences' Insight:

Availability:

huPBMC-NOG mice are produced upon order and delivered within one week of injections.

Color:

Albino

Species:

Mouse


Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

Conditions of Use specific to models generated using CRISPR/Cas9
This Model was generated using CRISPR/Cas9 technology. Taconic uses CRISPR/Cas9 technology to generate and/or distribute gene-edited models under licenses from The Broad Institute, Inc., the Massachusetts Institute of Technology, the President and Fellows of Harvard College, the University of Iowa Research Foundation and ERS Genomics. View the full list of licensed patents:
  • This Model and biological materials derived from it may only be used for purchasers' internal research purposes in the Field, unless purchaser otherwise has rights from the Broad covering such use. "Field" means use as a research tool for research purposes, and expressly excludes any (a) clinical use, (b) human, veterinary, livestock or agricultural use, or (c) manufacture, distribution, sale, promotion, use or other exploitation as a testing service, therapeutic or diagnostic for humans or animals.
  • The Models and biological materials derived from them will not be sold or used to perform services for third parties (unless purchaser is acting on behalf of a third party to which they have communicated these Conditions of Use and which third party has accepted these Conditions of Use), or otherwise used for commercial purposes.
  • Purchasers will only use the Models and biological materials derived from them in compliance with all applicable laws and regulations, including applicable human health and animal welfare laws and regulations.
  • Each non-profit purchaser agrees that it, and not Taconic's licensors, shall be responsible for any liability, damage, loss or expense arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them , including any breach of the Label License "Conditions of Use for Taconic Transgenic Models" by purchaser.
  • Each for-profit purchaser further agrees that it shall indemnify, defend and hold harmless Taconic's licensors against any liability, damage, loss, or expense (including without limitation reasonable attorneys' fees and expenses) incurred by or imposed upon any of Taconic's licensors in connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them.
  • Each purchaser acknowledges that the purchased Models and any biological materials derived from them and its use may be the subject of one or more issued patents and/or pending patent applications owned by Taconic's licensors, and the purchase of the Models does not convey a license under any claims in the foregoing patents or patent applications.
Base pricing is $500/€425 per mouse. The typical lead time for a cohort of standard huPBMC-NOG is 1-2 weeks upon placing purchase order. Please inquire for more details or to place your order. Information of the age, sex, and number of NOG mice, dose of PBMC/mouse (standard is 10M), and requirement of irradiation (standard is not to irradiate) would be required to complete the order.
huPBMC-NOG mouse chart #1
Chart #1: Human CD45+ cells were enumerated by flow cytometry at daily intervals follow PBMC engraftment. Significant engraftment was observed after 14 days. The majority of human CD45+ cells are CD3+ T cells.


huPBMC-NOG mouse chart #2
Chart #2: Irradiation exacerbates GvHD in PBMC engrafted NOG mice. Survival curves for PBMC engrafted NOG mice at increasing doses of radiation with, or without pre-treatment with anti-TNFa blocking antibody.